ANKK1

Ankyrin repeat and protein kinase domain-containing protein 1 · Q8NFD2 · ANKK1 on Sugi Atlas →

487 patent compounds predicted against ANKK1, 445 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Gsk-461364 (SCHEMBL310080)	1.00	1/20
Gsk-461364 (SCHEMBL4276841)	1.00	1/20
Gsk-461364 (SCHEMBL29360650)	1.00	1/20
Gsk-461364 (SCHEMBL29655945)	1.00	1/20
SCHEMBL19196385	0.91	1/20
SCHEMBL25660820	0.89	1/20
SCHEMBL2973906	0.88	1/20
SCHEMBL2973537	0.86	1/20
SCHEMBL4405982	0.86	1/20
SCHEMBL4562944	0.86	1/20
SCHEMBL13573235	0.86	1/20
Hydrochloric Acid (SCHEMBL3107975)	0.85	1/20
Hydrochloric Acid (SCHEMBL3111856)	0.85	1/20
SCHEMBL14029636	0.85	1/20
SCHEMBL25660819	0.85	1/20
Hydrochloric Acid (SCHEMBL4398123)	0.83	1/20
Hydrochloric Acid (SCHEMBL4541913)	0.83	1/20
SCHEMBL25227565	0.83	1/20
SCHEMBL25227566	0.83	1/20
SCHEMBL11923420	0.82	1/20

Clinical trials — most relevant to ANKK1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion	PHASE4	RECRUITING
Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity	PHASE4	COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy	PHASE2	RECRUITING
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
The Response To Ajmaline Provocation in Healthy Subjects	PHASE2	UNKNOWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b	PHASE1	COMPLETED
Delineating the Molecular Spectrum and the Clinical, Imaging and Neuronal Phenotype of Chopra-Amiel-Gordon Syndrome	nan	RECRUITING
Role of Nitric Oxide in Diabetic Patients With Erectile Dysfunction	nan	COMPLETED
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives	nan	UNKNOWN
Immune Cell Response to Stimuli	nan	RECRUITING
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING
Biomarkers in SCOTland CardiomyopatHy Registry (Bio-SCOTCH)	nan	RECRUITING
Changes in Skin Innervation of Neurologically Asymptomatic Type 2 Diabetic Patients: the Correlation With the Diabetic Parameters and Neurotrophins.	nan	UNKNOWN
Association of SNPs in Long Intergenic Noncoding RNA 00511 (LINC00511) With Breast Cancer Among the Egyptian Population	nan	COMPLETED
A Family Study of Copy Number Variations in Patients With Autism Spectrum Disorder	nan	COMPLETED
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial	nan	RECRUITING
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies	nan	RECRUITING
Biomarker Research in Inherited Movement Disorders	nan	RECRUITING
Mayo AVC Registry and Biobank	nan	RECRUITING
Pediatric Cardiomyopathy Mutation Analysis	nan	RECRUITING
PCM1-JAK2 in Therapy Related Neoplasms	nan	UNKNOWN
Idiopathic Dilated Cardiomyopathy	nan	COMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
Study of the Genetic Factors Involved in Autism and Related Disorders	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a ANKK1 binder may also engage these)

Protein	Name	Similarity
Q8BZ25	—	0.992	Q8BZ25 →
Q9ERK0	—	0.990	Q9ERK0 →
DAPK1	Death-associated protein kinase 1	0.988	landscape →
Q80YE7	—	0.988	Q80YE7 →
RIPK4	Receptor-interacting serine/threonine-protein kinase 4	0.987	landscape →
JAK3	Tyrosine-protein kinase JAK3	0.986	landscape →
Q8WXK4	—	0.985	Q8WXK4 →
Q5DU56	—	0.983	Q5DU56 →
Q08E43	—	0.983	Q08E43 →
Q2T9W8	—	0.982	Q2T9W8 →
A6NHY2	—	0.982	A6NHY2 →
Q9BGT9	—	0.982	Q9BGT9 →
Q5TYM7	—	0.982	Q5TYM7 →
Q4R544	—	0.981	Q4R544 →
Q9Y4C4	—	0.981	Q9Y4C4 →
Q02357	—	0.981	Q02357 →
Q3UHC2	—	0.980	Q3UHC2 →
Q00495	—	0.980	Q00495 →
P10421	—	0.980	P10421 →
Q5RCY1	—	0.980	Q5RCY1 →
Q9D738	—	0.980	Q9D738 →
P16157	—	0.980	P16157 →
PHKG2	Phosphorylase b kinase gamma catalytic chain, liver/testis isoform	0.980	landscape →
P32593	—	0.980	P32593 →
P35546	—	0.980	P35546 →
TNKS	Poly [ADP-ribose] polymerase tankyrase-1	0.980	landscape →
Q63272	—	0.980	Q63272 →
A4IIK1	—	0.980	A4IIK1 →
D3ZEY4	—	0.979	D3ZEY4 →
Q01484	—	0.979	Q01484 →